Skip to main content
OpenTrials
Completed

NCT Number: NCT06856876

Examining the Effectiveness of Multidisciplinary Care Teams in Improving Outcomes for Breast Cancer Patients

To compare clinical outcomes, patient-reported measures (PROMs), and healthcare utilization between standard care with or without an MDCT in a cohort of women treated for breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancers Breast Cancer Female Breast Cancer Stage I Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Hayatabad Medical Complex

Peshawar, KPK, 25000, Pakistan

About this study

This single-center, prospective interventional trial evaluates the effectiveness of Multidisciplinary Care Teams (MDCTs) in improving outcomes for newly diagnosed breast cancer patients at Hayatabad Medical Complex, Peshawar. The study enrolled 73 participants from May 2021 to April 2024, with follow-up sessions every six months for up to two years.

Participants were randomly assigned to two groups:

Group A (n=37): Received care through MDCTs, which included radiologists, oncologists, and surgeons collaborating to create personalized treatment plans and monitor patient progress.

Group B (n=36): Received standard therapy according to existing institutional protocols.

The study assesses multiple outcomes, including **disease-free survival (DFS), overall survival (OS), recurrence rates, complication rates, patient-reported outcomes (PROs), quality of life (measured via SF-36), and healthcare utilization.

Statistical analyses include Kaplan-Meier survival curves, log-rank tests, Cox proportional hazards regression models, repeated-measures ANOVA, and linear regression models to identify predictors of survival and quality of life.

The study protocol was approved by the Institutional Review Board (IRB) and complies with the Declaration of Helsinki. All participants provided informed consent prior to enrollment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All female patients, diagnosed with breast cancer

Exclusion criteria

Previous treatment for breast cancer, concurrent enrollment in another clinical research, and serious medical conditions that could affect study outcomes

Treatment and study plan

Multidisciplinary Care Team (MDCT) Approach

Other

A personalized breast cancer treatment plan developed through regular case discussions by a team of radiologists, oncologists, and surgeons. The MDCT coordinates patient support services and tracks treatment progress according to evidence-based guidelines.

Other names: MDCT

Standard Breast Cancer Therapy

Other

Breast cancer treatment provided according to the institutional protocols at Hayatabad Medical Complex, including standard surgery, chemotherapy, and/or radiotherapy as clinically indicated.

Other names: Standard Therapy

Primary outcomes

  1. Disease-Free Survival (DFS)

    Time frame: 24 months (measured at 6, 12, 18, and 24 months)

    Time from the start of treatment to the first occurrence of disease relapse, progression, or death from any cause.

  2. Overall survival

    Time frame: 24 months (measured at 6, 12, 18, and 24 months)

    Time from the start of treatment until death from any cause.

Secondary outcomes

  1. Recurrence rate

    Time frame: 24 months (measured at 6, 12, 18, and 24 months)

    Number of participants with local or distant breast cancer recurrence.

  2. Complication rate

    Time frame: 24 months (measured at 6, 12, 18, and 24 months)

    Incidence of treatment-related complications (e.g., surgical site infections, chemotherapy side effects).

Sponsors and collaborators

Lead sponsor

Yousaf Jan

Other Gov

Registry information

Acronym: MDCT

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Mar 4, 2025
Registry last updated
Mar 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.